BOT - Anything but charting, page-9412

I've been researching the history of Qbrexza and company Dermira. Worth a read on the below links for any one interested.

TLDR:
- Took nearly 15-years to come to market with FDA approval in June 2018

- (Dermira expands portfolio of drugs incl Phase 3 trials of Lebrikizumab for treatment of moderate-to-severe atopic dermatitis. Granted Fast Track designation from the U.S. Food and Drug Administration (FDA) in December 2019)

- Dermira Reports First Quarter 2019 Financial Results for QBREXZA: In the first quarter of 2019, generated 23,559 prescriptions for QBREXZA as reported by Symphony PHAST monthly data and 18,384 prescriptions as reported by IQVIA monthly data and the company’s preferred dispensing partner, in each case representing an increase of approximately 59% over the fourth quarter of 2018.

- "Today, more than 50,000 patients have received Qbrexza and just over 16,000 healthcare professionals have prescribed the therapy" - 2020, January

- Eli Lilly to add Dermira with $1.1 billion deal. ~$18 per share. 2020, January.

- (Unrelated but Lebrikizumab was approved in 16 May 2024 - 4 years after buyout).

Sources:
Q1 2019 FINANCIAL RESULTS
https://www.sec.gov/Archives/edgar/data/1557883/000119312519139641/d742335dex991.htm

HISTORY TIMELINE:
https://www.dermatologytimes.com/view/spotlight-dermira-and-qbrexza-story

BUYOUT - 2020,
https://www.prnewswire.com/news-releases/lilly-announces-agreement-to-acquire-dermira-300984850.html